Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
fingolimod (gilenya) (1 trial)
Amyotrophic Lateral Sclerosis (Phase 2)
Motor Neuron Disease (Phase 2)
Sclerosis (Phase 2)
Trials (1 total)
Trial APIs (1 total)